GBI Research, the leading
business intelligence provider, has released its latest research,
''Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased
Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'',
which provides in-depth analysis of hypertension therapeutics market within the
eight major geographies of the US, the top five European countries (the UK,
France, Germany, Spain and Italy), Japan and Canada. The report provides an
estimation of market size for 2013, along with market forecast until 2020. It
also covers disease epidemiology, treatment algorithms, treatment patterns,
in-depth analysis of the pipeline, and deal analysis.
Browse
Full Report With TOC @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries
The value of the hypertension
market in the major developed markets amounted to an estimated $40.0 billion in
2013 and is expected to decline during the forecast period at a negative
Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with
growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter.
The initial growth will be due to the increased penetration of fixed-dose
combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT,
Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in
the prevalence population from 181 million to 190 million at a CAGR of 0.6%,
and two new expected launches in the pipeline (azilsartan + amlodipine, and
AHU377+ valsartan). However, due to the expiry of the exclusivity of major
drugs both before and during the forecast period (Cozaar in 2010; Diovan,
Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and
Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate,
the market will decline from 2017.
Scope
The report analyzes treatment
usage patterns, market characterization, pipeline analysis and key licensing
and co-development deals in the hypertension in the major developed markets.The
report includes -
- Disease overview, as well as
treatment algorithms and treatment use patterns
- Market size and forecast for
the hypertension market from 2013-2020
- Major marketed products for
hypertension along with a heat map of product performance
- In-depth pipeline analysis for
global pipeline in hypertension along with clinical trial failure rate analysis
- Key drivers and restraints that
have had and are expected to have a significant impact upon the market
-
Key licensing and co-development agreements that could have impact on growth
trends
About Radiant
Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
For More
Information, Visit Radiant
Insights
Contact:
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
Phone:
1-415-349-0054
Toll
Free: 1-888-202-9519
Email:
sales@radiantinsights.com
No comments:
Post a Comment